US 11,912,660 B2
S6K1 protein kinase inhibitors as cancer therapeutics
Jayalakshmi Sridhar, New Orleans, LA (US); Melyssa Bratton, New Orleans, LA (US); and Rajesh Komati, Thibodaux, LA (US)
Assigned to Xavier University of Louisiana, New Orleans, LA (US)
Filed by Xavier University of Louisiana, New Orleans, LA (US)
Filed on Apr. 16, 2021, as Appl. No. 17/232,469.
Claims priority of provisional application 63/011,765, filed on Apr. 17, 2020.
Prior Publication US 2021/0323919 A1, Oct. 21, 2021
Int. Cl. C07D 209/56 (2006.01); A61K 45/06 (2006.01)
CPC C07D 209/56 (2013.01) [A61K 45/06 (2013.01)] 14 Claims
 
1. A compound according to formula (IIa) or formula (IIb), a stereoisomer, pharmaceutically acceptable salt and/or solvate thereof:

OG Complex Work Unit Chemistry
wherein
R is H;
X is —NH2;
R1 is NR5COR5;
R2 and R3 are each independently selected from the group consisting of H and NR5COR5;
R4 is selected from the group consisting of H, halogen, C1-6 alkyl, C1-6 alkenyl, C1-6 alkoxy, C1-6 haloalkyl, haloC1-6 alkoxy, —COOH, —CONH2, —COC1-6 alkyl, O—C1-6 alkyl, NH—C1-6 alkyl, —S C1-6 alkyl groups, —CN, —NH2, and —NO2; and
R5 is selected form the group consisting of H, aryl, C3-8 cycloalkyl, monocyclic or bicyclic heterocyclyl, and monocyclic or bicyclic heteroaryl, wherein the aryl, heteroaryl or heterocyclyl groups may be optionally substituted by one or more R4 groups.